Success strategies for cell and gene therapy 3.0

Advanced therapies are at the forefront of innovation in medical science – and with over 5,000 unique therapy products in development, the industry shows no signs of slowing. “CGT 3.0” represents the new wave of cell and gene therapies (CGTs), with allogeneic therapies and therapies aimed at treating solid tumors being two of the highest growth areas. New therapy types are exciting and hold promise for advancing treatment options, but they bring new types and layers of operational complexity in workflows, starting material, and traceability. The industry is at a pivotal point in preparing for the scaling and industrialization required to treat larger patient populations and there is an opportunity to solve operational challenges facing “CGT 3.0” through a combination of innovation and proven success strategies. This article explores both the ongoing and new challenges facing the industry and presents relevant solutions to the challenges for allogeneic and solid tumor therapies in the interest of supporting the development and widespread access and adoption of safe CGTs.

Please enter your email to access content Read now